SMPD1

Across TCGA pan-cancer cohorts, SMPD1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMPD1 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher SMPD1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMPD1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KICH, UCEC, and PRAD are the cancer types where SMPD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.025	0.904	<.001	36	view →
UCEC	OS	Median	All	0.963	0.650	.019	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	OS	Median	II,III,IV	0.547	0.852	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMPD1–KICH (DFS)

Open the KICH breakdown →